Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving Chemotherapy

A Multi-centers, Randomized, Open-labeled, Positive-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF, Once-per-cycle, in Patients With Malignancies Receiving Myelosuppressive Chemotherapy.

This phase 3 study is aimed to evaluate the safety and efficacy of YPEG-rhG-CSF in reducing the infection manifested by febrile neutropenia in patients with non-myeloid malignancy who receiving Myelosuppressive Chemotherapy which is likely to cause clinically significant febrile neutropenia.

Study Overview

• Status: Completed
• Conditions: Non-Myeloid Malignancy
• Intervention / Treatment: Drug: YPEG-rhG-CSF; Drug: YPEG-rhG-CSF; Drug: rhG-CSF/PEG-rhG-CSF

• Study Type: Interventional
• Enrollment (Actual): 398
• Phase: Phase 3

Contacts and Locations

Study Locations

• China
  • Beijing
    • Beijing, Beijing, China
      • Cancer Hospital Chinese Academy of Medical Sciences

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Histopathology and/or cytology diagnosed as breast cancer (BC) or non-small cell lung cancer (NSCLC), and patients with breast cancer is suitable to receive TAC(Docetaxel,Doxorubicin combined with Cyclophosphamide) chemotherapy, while patients with NSCLC is suitable to receive DC(Docetaxel combined with Carboplatin) chemotherapy.
• Age ≥18 yrs.
• Weight ≥45 kg.
• Karnofsky Score ≥ 70.
• Life Expectancy ≥ 3 months.
• Peripheral blood test: WBC≥3.5×10^9 cells/L, PLT≥100×10^9 cells/L. ANC≥1.5×10^9 cells/L.
• Understand and voluntarily sign the informed consent form.

Exclusion Criteria:

• Receiving chemotherapy within two months prior to screening.
• Previously or plan to receive radiotherapy (>25% total bone marrow volume).
• Evidence of tumor metastasis in bone marrow.
• Lack of awareness.
• Uncontrolled infection or using of antibiotics within 72hrs prior to screening.
• Previously received or plan to undergoing bone marrow or organ transplants.
• Patients with bleeding tendency, e.g. prolonged prothrombin time of more than 3 seconds.
• Dysfunction in heart,lung, liver, kidney, or other major organs or systems; ALT>2.5 ULN (upper limit of normal), TBil >2.5 ULN (ALT>2.5 ULN, total bilirubin >2.5 ULN for patients with liver metastasis), HBsAg positive, anti-HCV positive, evidence of liver decompensation, or Cr >1.5 ULN.
• Pregnant or lactating females.
• Malignancy other than BC or NSCLC.
• Hypersensitivity to rhG-CSF or any component of the investigational Products.
• Subject enrolled in any other studies within 3 months prior to screening.
• Drug abuser or alcoholics.
• Any other conditions which in the opinion of the investigator precluded enrollment into the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: YPEG-rhG-CSF 2mg	Drug: YPEG-rhG-CSF; YPEG-rhG-CSF 2mg, single s.c. at day 3 of each cycles, up to 4 cycles. 21 day one cycles.; Drug: YPEG-rhG-CSF; YPEG-rhG-CSF 33μg/kg, single s.c. at day 3 of each cycles, up to 4 cycles. 21 day one cycles.
Experimental: YPEG-rhG-CSF 33μg/kg	Drug: YPEG-rhG-CSF; YPEG-rhG-CSF 2mg, single s.c. at day 3 of each cycles, up to 4 cycles. 21 day one cycles.; Drug: YPEG-rhG-CSF; YPEG-rhG-CSF 33μg/kg, single s.c. at day 3 of each cycles, up to 4 cycles. 21 day one cycles.
Active Comparator: Positive Control Group; rhG-CSF/PEG-rhG-CSF	Drug: rhG-CSF/PEG-rhG-CSF; rhG-CSF 5μg/kg/day, s.c. from day 3 to day 14 or until neutrophils recover to exceed 5.0×10^9 cells/L, whichever comes first, in the first cycle. Patient can still continue rhG-CSF 5μg/kg/day, or covert to PEG-rhG-CSF 6mg/Cycle in the following 2-4 cycle. 21 day one cycles.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean Duration of Severe Neutropenia (DSN) During Cycle 1.	Mean duration of severe neutropenia, defined as number of consecutive days with absolute neutrophil count (ANC) <0.5 × 10^9 cells/l (grade 4 neutropenia)	At the end of Cycle 1 (21 days one cycle)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of Febrile neutropenia(FN).	FN defines as the ANC counts is less than < 0.5 × 10^9 cells/L or ANC counts between 0.5 × 10^9 cells/L and 1.0 × 10^9 cells/L but probably to decline to less than 0.5×10^9 cells/L within 48hrs, and body temperature is higher than 38.3 degrees Celsius or higher than 38.0 degrees Celsius and lasting for more than 1hr.	Cycle1 to Cycle 4(21 days one cycle)
Mean duration of DSN.		Cycle2 to Cycle 4 (21 days one cycle)
Incidence of Grade 3 neutropenia.	Grade 3 neutropenia defines as the ANC count is less than 1.0×10^9 cells/L.	Cycle1 to Cycle 4 ( 21 days one cycle)
Mean duration of grade 3 neutropenia.		Cycle1 to Cycle 4(21 days one cycle)
Neutrophils dynamic changes from baseline.		Cycle1 to Cycle 4 ( 21 days one cycle)
Time of neutrophils recovering to over 2.0×10^9 cells/L after nadir.		Cycle1 to Cycle 4 (21 days one cycle)
Proportion of patients with antibiotic usage.		Cycle1 to Cycle 4 ( 21 days one cycle)
Proportion of patients experienced infection.		Cycle1 to Cycle 4 ( 21 days one cycle)
Proportion of patients fulfilling expected chemotherapy.		Cycle1 to Cycle 4 (21 days one cycle)

Collaborators and Investigators

• Sponsor: Xiamen Amoytop Biotech Co., Ltd.
• Collaborators: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Study record dates

Study Major Dates

• Study Start (Actual): October 16, 2020
• Primary Completion (Actual): June 24, 2021
• Study Completion (Actual): September 1, 2021

Study Registration Dates

• First Submitted: June 29, 2020
• First Submitted That Met QC Criteria: July 6, 2020
• First Posted (Actual): July 10, 2020

Study Record Updates

• Last Update Posted (Actual): February 9, 2022
• Last Update Submitted That Met QC Criteria: February 7, 2022
• Last Verified: January 1, 2022

More Information

Terms related to this study

• Keywords: Neutropenia; G-CSF; Febrile Neutropenia; Human Granulocyte Colony-Stimulating Factor; Myelosuppressive Chemotherapy; FN
• Additional Relevant MeSH Terms: Neoplasms
• Other Study ID Numbers: TB1801CSF

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No